An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A Chinese biotech company called Ascletis has started the first early-stage (Phase I) human trial in the U.S. of a new oral drug called ASC36. The company says ASC36 is a peptide that acts on the amylin receptor and that they are testing it as a treatment for obesity. This announcement means the drug has moved from lab and animal work into testing in people for the first time in the U.S. ASC36 is described as an amylin receptor peptide agonist. In plain language: amylin is a natural hormone that your body releases with insulin after you eat. It helps signal fullness, slows how quickly the stomach empties, and affects blood sugar control. A “peptide” is a short chain of amino acids — basically a tiny protein-like molecule. An “agonist” means ASC36 is designed to mimic amylin’s action and activate the same receptor in the body. Unlike many approved diabetes and weight-loss drugs that are injected, Ascletis says ASC36 is oral — taken by mouth. The news itself is about the start of a Phase I trial, which typically tests safety, tolerability, and how the body handles the drug (absorption and dosing) in a small number of healthy volunteers or patients. The announcement doesn’t provide detailed results because the trial has just begun. So there’s no evidence yet in humans showing it helps people lose weight. We don’t know how many participants are enrolled, how long the trial will run, or whether the drug has shown convincing benefit in animals or earlier studies—only that the company has clearance to start these initial human tests. This matters because oral options for hormones like amylin could be more convenient than injections. If ASC36 works and is safe, it could expand the range of treatments for people with obesity who prefer pills over injectables. It also shows continued industry interest in targeting satiety and digestion to reduce weight, not just appetite. For someone following weight-loss drug developments, this is an early signal to keep an eye on — but it’s far from proof of effectiveness. Important caveats: Phase I trials are primarily about safety and dosage, not whether the drug works long-term. Many drugs that look promising in early tests don’t succeed in larger trials. Peptide drugs can face challenges being absorbed when taken by mouth, so “oral” claims deserve scrutiny in later results. Side effects for amylin-type drugs can include nausea and digestive upset; we don’t yet know ASC36’s side effect profile. Also, regulatory approval will require larger and longer studies; starting a Phase I trial does not mean the drug is approved or proven. Bottom line: Ascletis has begun first-in-human testing in the U.S. of an oral amylin-mimicking peptide for obesity — an interesting early step, but no proof yet that it will be safe or effective.
Source: Yahoo Finance